We observe that the quartile of individuals with the highest GLP-1 response have a ~ 5 mmHg lower blood pressure compared to the quartile of individuals with the lowest GLP-1 response. A large meta-analysis found that the degree of blood pressure reduction was proportional to the risk of major cardiovascular disease events, stroke, heart failure, and all-cause mortality [
31]. Interestingly, a reduction of 4.5 mmHg in systolic blood pressure has been associated with lower risk of cardiovascular event, all-cause mortality and cardiovascular mortality [
32]. Thus our finding of a 5 mmHg difference in blood pressure between GLP-1 response groups is of clinical relevance with regards to mortality. In comparison, DPP-4 inhibitors reduce systolic blood pressure by 2.5–2.8 mmHg [
33‐
35] and GLP-1 RAs reduce systolic blood pressure by 1.2–4 mmHg [
4,
5,
36]. GLP-1 RAs [
4,
5,
37] have, furthermore been found to reduce risk of major adverse cardiac events which has not been observed for DPP-4 inhibitors [
38‐
40].
The GLP-1 receptor has been located on endothelial cells in the vasculature [
41] and a direct effect of GLP-1 on vascular smooth muscle has also been proposed [
42]. This may be one of the mechanisms by which GLP-1 RA treatment decreases blood pressure. Endothelial dysfunction, characterized by reduced nitric oxide (NO) production, is a precursor of atherosclerosis and a risk factor for CVD [
43]. GLP-1 treatment promotes vasodilation by production of NO [
44]. Insulin has also been shown to induce NO production [
45], however, the association in our study remained significant when adjusting the analyses for insulin (see Fig.
2), indicating that GLP-1 works independently of insulin on the blood pressure-lowering mechanism. Infusion of GLP-1 in physiological doses exerted vasodilatory actions, decreased diastolic blood pressure and increased heart rate whereas systolic blood pressure was unchanged in a study of 26 healthy individuals [
15]. Furthermore, treatment with GLP-1 RAs have shown to improve arterial stiffness in type 2 diabetes [
46], which is augmented by hypertension [
47]. Similarly, treatment with DPP-4 inhibitors have shown to improve intima-media thickness [
48], arterial stiffness [
49] and diastolic dysfunction [
50,
51], which are all factors associated with blood pressure [
52,
53]. In our study of individuals without diabetes and hypertension we did not find an association between GLP-1 response and PWV (Table
2), a measurement of arterial stiffness, or central pulse pressure (Fig.
2), which is determined by arterial stiffness [
47]. To further support the effect of GLP-1 RAs on endothelial cells, liraglutide has also been found to have anti-restenotic effects mediated by endothelial NO [
54]. Endothelial cells do not only play a role in NO production, they also influence on the angiogenesis process [
55] and liraglutide has been found to promote angiogenesis after stroke [
56] opening up for the possibility that GLP-1-based treatment potentially could be applied as a neuroprotective drug as well as a cardioprotective, anti-hyperglycemic and anti-obesity drug.